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OBJECTIVES The goal of this study was to determine the prevalence of valvular regurgitation and abnormal
valve morphology in patients three to five months after discontinuation of dexfenfluramine
(Dexfen) therapy.
BACKGROUND We previously reported the results of a randomized, double-blind, placebo-controlled trial of
valvular structure and function in 1,073 patients treated either with Dexfen, with an
investigational sustained-release dexfenfluramine (Dexfen SR), or with a placebo, with
echocardiograms performed approximately one month from the last dose. Using FDA criteria
(aortic regurgitation [AR] $mild and/or mitral regurgitation [MR] $moderate) we found no
statistical difference among the groups, but when all degrees of valvular regurgitation were
considered and when the two Dexfen groups were combined, there was a higher prevalence
of any degree of AR, any degree of MR, and restricted posterior mitral leaflet mobility.
However, it was unknown whether these differences in prevalence persisted.
METHODS The double blind was maintained, and all patients were invited to return for a follow-up
echocardiogram. Echocardiograms were acquired using a standardized protocol and assessed
blindly to determine the degree of valvular regurgitation and valve leaflet thickness and
mobility. We had an 80% power to detect a statistically significant change in paired
proportions using the McNemar test (alpha 5 0.05).
RESULTS Echocardiograms were obtained on 941 patients with a median of 137 days after drug
discontinuation. Aortic regurgitation (of any degree) was present in 13.8% of Dexfen (p 5
0.41 compared to placebo), 10.7% of Dexfen SR (p 5 0.64 compared to placebo), and 11.9%
of placebo patients. The minor differences between patients treated with active drug versus
placebo, which were found in the previous study, were no longer significant even when the
groups were combined (p 5 0.83 compared to placebo). Mitral regurgitation (of any degree)
was present in 71.5% (p 5 0.15 compared to placebo), 69.8% (p 5 0.30 compared to placebo),
and 70.5%, respectively. This was also not significantly different from placebo when both
Dexfen groups were combined (p 5 0.16). There was no difference in the prevalence of
restricted posterior mitral leaflet mobility among the three groups (p 5 0.19).
CONCLUSIONS The small increase in prevalence of minor degrees of AR and MR in patients treated with two
to three months of Dexfen previously reported is no longer present three to five months after
discontinuation of medication. These data suggest that the degree of regurgitation observed
in patients who used Dexfen for a relatively short duration does not progress over time. (J Am
Coll Cardiol 1999;34:2088–95) © 1999 by the American College of Cardiology
Dexfenfluramine (Dexfen) and other anorectic agents have
been used alone or in combination for appetite suppression.
In July 1997, physicians at the Mayo Clinic/Merit Care (1)
reported valvular abnormalities in 24 patients treated with
phentermine/fenfluramine (phen-fen) (2). Since that time,
many other reports have addressed various aspects of this
issue and have provided a wide range of estimates for the
prevalence of heart valve abnormalities associated with
appetite suppressants (3–27).
At the time Dexfen was voluntarily withdrawn from the
market (September 1997), an ongoing, randomized,
double-blind, placebo-controlled study comparing Dexfen,
an investigational sustained-release formulation of dexfen-
fluramine never marketed (Dexfen SR), and placebo was
amended to discontinue study medication and perform
echocardiographic examinations. Using Food and Drug
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Administration (FDA) criteria (AR [aortic regurgitation]
$mild and/or MR [mitral regurgitation] $moderate), an
analysis of the echocardiograms, performed approximately
one month after study medication was discontinued, found
no statistical difference among the groups. When all degrees
of valvular regurgitation were considered and when the two
Dexfen groups were combined, there was a higher preva-
lence of any degree of AR (p 5 0.03), any degree of MR
(p 5 0.01), and restriction of posterior mitral leaflet
mobility (p 5 0.02) (28). To determine whether the
increased prevalence of minor valvular abnormalities in
treated patients as compared to placebo persisted after
discontinuation of Dexfen, the double blind was maintained
and all patients from the original study were invited to
return for a follow-up echocardiogram approximately three
months after the first echocardiogram. We report the
echocardiographic findings performed three to five months
after study medication was discontinued.
METHODS
Study design. This study was originally designed as a
randomized, double-blind, parallel group, placebo-
controlled study comparing the efficacy and safety of inves-
tigational sustained-release dexfenfluramine (Dexfen SR)
(30 mg once a day) with the immediate release formulation
of Dexfen (15 mg BID [twice a day]) and placebo. The
study design and demographics of the original trial have
been reported previously (28).
Patients. Patients who participated in the randomized
study were men and women 18 years of age or older with a
body mass index of at least 30 kg/m2 (kilogram per square
meter) or 27 kg/m2 accompanied by hypertension, hyper-
lipidemia, and/or diabetes mellitus. Patients were ineligible
on entry if they had unstable cardiovascular or other
systemic disorders, or had obesity secondary to endocrinop-
athy. Patients with a history of pulmonary hypertension or
other disorders listed in the product labeling were ineligible
to participate in the original study. The recent or concurrent
use of selective serotonin reuptake inhibitors, other anorec-
tic agents or Dexfen (Redux™) within six months of
randomization in the study was prohibited, and patients
agreed not to begin these medications until after the
follow-up echocardiogram was complete.
Echocardiographic assessments. Echocardiograms were
performed locally using a standardized imaging protocol as
previously described (28). The degree of mitral (MR), aortic
(AR), and tricuspid regurgitation was assessed by color
Doppler in multiple views. Technical inability to evaluate
one valve did not preclude examination of the remaining
valves. Severity of MR was visually rated as none, physiologic,
mild, moderate, severe, or not evaluable (29). Severity of AR
was visually rated as none, trace, mild, moderate, severe, or not
evaluable (30). Mitral, aortic, and tricuspid valve leaflet
thickness and mobility were also assessed in multiple views
as previously described (28, 31). Pulmonary artery pressure
was estimated from tricuspid regurgitation velocity using
the modified Bernoulli equation and assuming a right atrial
pressure of 10 mm Hg (32). Echocardiographic interpreta-
tions were performed at an independent central laboratory
by cardiologists (N.J.W., J.F.T., J.S.G.) blinded to patient
treatment.
Reader variability. Echocardiograms were evaluated by
a second independent reviewer when any of the following
criteria were met: thickening of any valve leaflet; re-
stricted valve leaflet mobility $moderate; AR $mild;
MR $moderate, or tricuspid regurgitation $moderate. All
discrepant readings were resolved by consensus readings. A
random sample of additional echocardiograms were read by
two readers to evaluate interreader agreement, and each
reader reread a random sample of echocardiograms to
evaluate intrareader agreement.
Statistical analyses. Demographics among treatment
groups at the follow-up visit were compared using analysis
of variance and chi-square tests. The FDA criteria of mild
or greater AR and/or moderate or greater MR was used to
dichotomize valvular regurgitation as present or absent. The
proportions of patients in each group who met the FDA
criteria were calculated, and the Fisher exact test was used to
determine whether significant differences existed among the
three treatment groups. The 95 percent confidence intervals
(CIs) for crude odds ratios (ORs) for each active treatment
group versus placebo were calculated using large-sample
normal approximations. The nonparametric Kruskal-Wallis
test was used to determine whether significant treatment
differences existed with respect to any grade of valvular
regurgitation. Separate analyses were performed for the
aortic, mitral, and tricuspid valves. The Kruskal-Wallis test
was also used to determine significant treatment differences
with respect to the four grades of restricted mobility (none,
minimal, moderate, and severe). The McNemar test for
correlated proportions was used to determine whether
significant changes existed in valvular regurgitation from the
initial to the follow-up echocardiogram. We performed a
power analysis to estimate the necessary sample size to
detect a statistically significant change in prevalence. Based
Abbreviations and Acronyms
AR 5 aortic regurgitation
BID 5 twice a day
Dexfen 5 dexfenfluramine
Dexfen SR 5 sustained-release formulation of
dexfenfluramine never marketed
kg/m2 5 kilogram per square meter
LVOT 5 left ventricular outflow tract
MR 5 mitral regurgitation
phen-fen 5 phentermine/fenfluramine
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on a sample size of n 5 300 per treatment group, we had an
80% power to detect a statistically significant change in
paired proportions using the McNemar test with alpha 5
0.05, two-tailed, and a difference in proportions of 5%, with
10% of the pairs discordant.
The Kruskal-Wallis test was used to compare the change
distribution between the treatment groups and the control
group. Kappa statistics and percent concordance were used
to assess inter- and intrareader variability for echocardio-
graphic parameters. All reported p-values were nominal. All
statistical analyses were performed using the SAS statistical
software (SAS Corp., version 6.09, Cary, North Carolina).
RESULTS
Of the 1,213 patients from the original study, 941 returned
for the follow-up echocardiogram. The baseline demo-
graphic characteristics (Table 1) and median duration of
treatment (77 to 78 days) were similar for all groups. These
patients were predominantly obese, white, middle-aged
women who had an echocardiogram within a median of 137
days after drug discontinuation (138 days for placebo, 136
for Dexfen, and 136 for Dexfen SR). Overall, 85.3% of
patients were treated for eight weeks or longer, and 38.5%
percent for at least 12 weeks.
Two hundred and seventy-two patients (90 Dexfen, 90
Dexfen SR, 92 placebo) did not return for the follow-up
echocardiogram. The reasons for not returning were equally
distributed across the three groups, 167 refused, 92 were lost
to follow-up, 10 patients had echocardiography outside the
dates defined for this analysis; there was one death (gunshot
wound), one technical error (tape did not record), and one
patient was randomized but never took the assigned drug.
Of the 941 patients who had an echocardiogram at three
months, 919 had a previous one, and for the remaining 22
patients, the three-month echocardiogram was their first
ultrasound evaluation. At baseline the prevalence of FDA
criteria AR (4.8% vs. 4.9%, p 5 1.0) and prevalence of FDA
criteria MR (1.3% vs. 3.5%, p 5 0.063) were not statistically
different from those who did or did not return, respectively.
However, those who did return for echocardiography were
slightly older, were on therapy longer, were more often
hypertensive and less obese than were those who did not,
but none of these differences were statistically significant.
Echocardiographic results. VALVULAR REGURGITATION.
Most valves were adequately visualized. The aortic valve
could be evaluated for regurgitation in 881 echocardiograms
(93.6%) and mitral valve in 888 (94.4%).
Using the FDA criteria of mild or greater AR, the
prevalence rates (p-value vs. controls) for Dexfen, Dexfen
SR, and placebo-treated patients were 7.5% (p 5 0.16), 4%
(p 5 0.84), and 4.5%, respectively (Table 2). Using the
FDA criteria of moderate or greater MR, the prevalence
Table 1. Characteristics of the Follow-up Echocardiogram Groups
Characteristic
Dexfenfluramine
(n 5 314)
Sustained-Release
Dexfenfluramine
(n 5 314)
Placebo
(n 5 313)
Age (yrs)
Mean 6 SD 45.8 6 11.0 45.5 6 10.5 45.6 6 11.7
Gender (percent of group)
Female 81.5 76.8 81.2
Race (percent of group)
White 85.4 79.6 83.1
Black 10.8 16.6 12.5
Other* 3.8 3.8 4.4
Baseline weight (kg)
Mean 6 SD 105.4 6 20.7 105.6 6 20.9 104.9 6 20.9
Baseline body mass index (kg/m2)
Mean 6 SD 38.4 6 6.6 38.0 6 7.0 38.5 6 6.7
Hypertensive patients (percent of
group)
Yes 22.6 25.5 26.8
Duration of therapy
Mean 6 SD 72.5 6 22.5 72.0 6 22.5 72.0 6 22.0
Time from discontinuation of
drug to echocardiogram (days)
Mean 6 SD 143.8 6 30.5 143.1 6 30.7 145.0 6 32.3
Time from initial echocardiogram
to follow-up echocardiogram
(days)
Mean 6 SD 106 6 28 103 6 23 103 6 21
*Asian, Hispanic, Native American, and other.
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rates were 1.7% (p 5 1.0), 3.3% (p 5 0.30), and 1.7% in
these same groups (Table 2). No significant differences
among treatment groups were found using this FDA clas-
sification for the aortic or mitral valves. In addition, we
examined valvular regurgitation by all degrees of severity
(Table 3). Aortic regurgitation of any severity (including
trace) was detected in 41/295 (13.8%) Dexfen-treated pa-
tients, 32/300 (10.7%) Dexfen SR-treated patients, and
34/286 (11.9%) placebo-treated patients, and there were no
cases of severe AR. Mitral regurgitation of any severity
(including physiologic/trace) was detected in 211/295
(71.5%) Dexfen-treated patients, 211/302 (69.8%) Dexfen
SR-treated patients, and 205/291 (70.5%) placebo-treated
patients. Most cases of MR were physiologic (53.6% to
61.2%) and mild (7.6% to 14.9%), and there were no cases
of severe MR. No statistically significant differences existed
in grade (Kruskal-Wallis test) for AR or MR among the
three treatment groups including pairwise comparisons.
Furthermore, we undertook additional analyses combining
the two active treatment groups, and there were still no
statistically significant differences versus the placebo group
for either MR or AR (Tables 2 and 3).
Table 2. Prevalence of FDA-Defined Mitral and Aortic Valvular Regurgitation by Treatment Group*
Valve Categories Dexfenfluramine
Sustained-Release
Dexfenfluramine
Combined
Dexfenfluramine
Groups Placebo
Aortic regurgitation
Number of evaluable valves† 295 300 595 286
FDA positive—present (%) 7.5 4.0 5.7 4.5
Odds ratio, (95% CI)‡ 1.69 (0.84, 3.43) 0.88 (0.39, 1.95) 1.27 (0.66, 2.45)
p-Value (pairwise vs. placebo) 0.16 0.84 0.52
Mitral regurgitation
Number of evaluable valves§ 295 302 597 291
FDA positive—present (%) 1.7 3.3 2.5 1.7
Odds ratio (95% CI)‡ 0.99 (0.28, 3.44) 1.96 (0.66, 5.80) 1.47 (0.53, 4.10)
p-Value (pairwise vs. placebo) 1.0 0.30 0.63
Aortic and/or mitral regurgitation
Number of evaluable valves†§ 292 299 591 284
FDA positive—present (%) 8.9 6.7 7.8 6.6
Odds ratio (95% CI)‡ 1.64 (0.86, 3.12) 1.20 (0.61, 2.37) 1.41 (0.79, 2.54)
p-Value (pairwise vs. placebo) 0.15 0.61 0.26
*Valvular regurgitation by FDA criteria. †Aortic regurgitation ,mild was considered absent and $ was considered present. ‡The odds ratio was based on the presence of
regurgitation in the two active-treatment groups individually and combined as compared with the placebo group. CI denotes the confidence interval. §Mitral
regurgitation ,moderate was considered absent, and regurgitation $moderate was considered present. Overall p values for MR, AR, MR/AR were not statistically significant.
Table 3. Prevalence of Aortic and Mitral Valvular Regurgitation by Severity and by Treatment Group
Valve Categories Dexfenfluramine
Sustained-Release
Dexfenfluramine
Combined
Dexfenfluramine
Groups Placebo
Aortic
No. of evaluable valves 295 300 595 286
None (%) 86.1 89.3 87.8 88.1
Trace (%) 6.4 6.7 6.6 7.3
Mild (%) 7.1 4.0 5.5 4.6
Moderate (%) 0.3 0 0.2 0
p-Value (Kruskal-Wallis)
(pairwise vs. placebo)
0.41 0.64 0.83
Mitral
No. of evaluable valves 295 302 597 291
None (%) 28.5 30.1 29.3 29.6
Physiologic (%) 54.9 53.6 54.3 61.2
Mild (%) 14.9 12.9 13.9 7.6
Moderate (%) 1.7 3.3 2.5 1.7
p-Value (Kruskal-Wallis)
(pairwise vs. placebo)
0.15 0.30 0.16
Overall p-values (Kruskal Wallis test): no statistical significance. There were no severe grades of mitral or aortic regurgitation.
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Similarly, no differences occurred in the prevalence or
severity of tricuspid or pulmonary regurgitation between
treated groups versus placebo.
VALVE MORPHOLOGY AND MOBILITY. All evaluable valve
leaflets were assessed for the presence or absence of leaflet
thickening and degree of restricted mobility. Aortic valve
morphology was similar among the three treatment groups.
Restricted mobility of any aortic leaflet was rare (#1%) and
not different among groups. No differences existed in the
prevalence of restricted posterior or anterior mitral leaflet
mobility among the three groups. No patient had thickening
or restricted mobility of the tricuspid leaflets.
PULMONARY ARTERY PRESSURE. Two hundred and sixty-
four patients, equally distributed among treatment groups,
had sufficient tricuspid regurgitation to estimate pulmonary
artery pressure. No significant difference was seen in mean
systolic pulmonary artery pressure (Dexfen 30.9 6
7.6 mm Hg, Dexfen SR 30.9 6 6.3 mm Hg, and placebo
30.5 6 5.8 mm Hg) among the treatment groups. Pulmo-
nary artery pressure greater than 40 mm Hg occurred in
seven, five, and five patients treated with Dexfen, Dexfen
SR, and placebo, respectively.
PAIRED ANALYSIS. We examined the change in AR and
MR for the subgroup of patients who had both an initial
and follow-up echocardiogram (Table 4). The data in Table
4 suggest that there may be a regression of AR in the
Dexfen SR group, but this is not statistically significant
when compared to placebo (p 5 0.15). The trend for an
upward shift in the detection of MR (Table 4) over time,
predominantly due to the detection of physiologic regurgi-
tation, is confirmed in the placebo group (p , 0.001).
Nonetheless, these data support the absence of progression
of either AR or MR in any treatment group when compared
to placebo.
READER VARIABILITY. Interreader variability was assessed
using a random sample from all echocardiograms (n 5 76)
as well as echocardiograms that met criteria for a second
evaluation (n 5 133). There was agreement on the presence
or absence of AR and/or MR (FDA criteria) in 75 of 76
(98.7%) of these echocardiograms. When evaluating the
presence or absence of AR and/or MR (FDA criteria) in
111 of 133 selected echocardiograms, there was a concor-
dance of 83.5% (average kappa 5 0.74). For intrareader
variability, there was 88.6% concordance (n 5 79) in
assessing the presence or absence of AR and/or MR
(average kappa 5 0.69). These variability results are similar
to those previously reported (28). Each cardiologist evalu-
ated approximately 15 tapes (n 5 40), read approximately
three months apart, to measure intrareader variability over
Table 4. Paired Analysis: Summary of Change From the Initial Echocardiogram to the Follow-up Echocardiogram
Aortic Regurgitation
Grade Change (Follow-
up Echocardiogram
Compared to Initial
Echocardiogram)
Dexfen
(n 5 282)*
Dexfen SR
(n 5 275)*
Placebo
(266)*
12 4 0 2
11 12 7 7
Equal 243 240 247
21 20 25 10
22 3 3 0
p-Value (McNemar test) 0.26 ,0.001 0.82
p-Value (Kruskal-Wallis;
pairwise vs. placebo)
0.51 0.15
Mitral Regurgitation
Grade Change (Follow-
up Echocardiogram
Compared to Initial
Echocardiogram) (n 5 283)* (n 5 282)* (n 5 273)*
12 6 2 6
11 75 88 72
Equal 163 149 160
21 37 42 34
22 2 1 1
p-Value (McNemar test) ,0.001 ,0.001 ,0.001
p-Value (Kruskal-Wallis;
pairwise vs. placebo)
0.77 0.53
*Number of evaluable pairs of valves. There were no 1/23 or 1/24 grade changes for aortic and mitral regurgitation.
11, 12 5 follow-up echocardiogram grade is one or two grades more severe than initial echocardiogram grade. 21, 22 5 follow-up echocardiogram grade is one or two
grades less severe than initial echocardiogram grade.
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time. There was no statistical difference between the first
and second evaluation of the aortic valve (p 5 0.53). When
evaluating the mitral valve, however, there was a statistically
significant trend toward a more severe interpretation of the
valve during the second reading (p 5 0.005). This change
was predominantly due to the detection of physiologic
regurgitation.
DISCUSSION
This current study found no difference between treated
groups and placebo for regurgitation or restricted leaflet
mobility after three to five months, even when considering
all degrees of valvular regurgitation and combining Dexfen
groups. This is in contrast to the previous study where we
also reported no statistical difference using the FDA criteria
(AR $mild and MR $moderate) but did report a higher
prevalence of any degree of AR and any degree of MR when
all degrees of valvular regurgitation were considered (28).
Although regression of minor valvular changes is possible,
many other factors could explain these findings.
All patients from the original study were invited to return
for an echocardiogram at both one and three months; of
these, 1,073 returned for the one-month echocardiogram
and 941 returned for the second echocardiogram. This
decrease was due to patient choice not to return and not to
serious adverse events. The drop-out rate at both time
intervals was equally distributed among treatment and
placebo groups. Nonetheless, the smaller patient population
may have resulted in a reduction of statistical power to
detect subtle differences at the later time period.
Moreover, there were subtle changes in the study popu-
lation that do not appear to have biased the assessment of
prevalence at follow-up. Of the 941 patients who underwent
an echocardiogram at three months, 919 had a previous one
and for the remaining 22 patients, the three-month echo-
cardiogram was their first ultrasound evaluation. The time
between initial and follow-up examinations for the 919
patients who had two examinations was similar among
groups. Because the prevalence of FDA criteria for AR and
MR in these subjects was not statistically different from
those subjects who did not return, it is unlikely that
selection bias was introduced.
However, once results from the initial echocardiograms
were reported, there was the potential for both echocardio-
graphic acquisition and interpretation to be skewed toward
positive findings. Examination of the prevalence of valvular
regurgitation in the placebo group for the one-month and
three-month echocardiograms demonstrates that this may
have occurred. For example, in the placebo group, MR of
any severity increased from 54.4% to 70.4%. This shift was
predominantly due to the detection of physiologic regurgi-
tation in a higher proportion of these subjects. Because of
the temporal drift, the validity of paired analysis to detect
change within the treated group may have been compro-
mised. In future studies, to minimize temporal drift, echo-
cardiograms should be interpreted concurrently, and blinded
to sequence.
Comparison to prior reports. The prevalence of valvular
abnormalities in this study is low and similar to most prior
reports. Because small degrees of valvular regurgitation are
prevalent in the general population (33), and because of the
inherent variability in echocardiography, studies with suffi-
cient sample size and adequate controls are necessary. Large
cohort studies (34–37) (greater than 100 subjects per group)
with adequate controls reported a prevalence (using FDA
criteria) of AR and MR similar to our results. Nonetheless,
there remains a wide range of reported prevalence rates (38,
39) and this may be due to differences in study population,
treatment drug, combination therapy, duration, selection or
reader bias, or possibly other factors.
Little information is available regarding the natural his-
tory of regurgitation occurring in anorexigen-treated sub-
jects. Connolly et al. (2) reported severe symptoms in some
patients leading to valve replacement despite the fact that
therapy had been discontinued. In contrast, Cannistra (40)
reported regression of multivalvular regurgitation in a
woman who had received phentermine/fenfluramine (phen-
fen). Although there are no prospective studies assessing the
natural history, a large, randomized, blinded, controlled
study, in patients treated with fenfluramine for three
months, reported by Davidoff and colleagues (41), failed to
find a difference in the prevalence of regurgitation between
treated and untreated subjects five years after cessation of
therapy. Shively (36) reported a lower prevalence of regur-
gitation in patients with late as opposed to early echocar-
diograms after discontinuation of Dexfen therapy, suggest-
ing the possibility of regression. Little information has been
reported on sequential echocardiograms on patients who
used appetite suppressants (42). Wee and colleagues per-
formed a retrospective survey of the echocardiographic
databases in two large hospitals and identified only 46
patients who had an echocardiogram prior to and after
appetite-suppressant therapy (42). Using the FDA case
definition, two patients (4.3%) showed progression and two
patients showed regression. Of the two patients who
showed progression, one had mild AR that progressed to
moderate in the presence of a bicuspid valve and there was
an eight-year period between echocardiograms in the other
patient. The present double-blind study provides longitudi-
nal echocardiograms acquired in a large, controlled popula-
tion. For patients treated with Dexfen for two to three
months, we found no difference in prevalence of valvular
regurgitation between treated patients and controls three to
five months after drug was discontinued, suggesting that
progression is extremely unlikely.
Study limitations. This study continues to have the limi-
tations discussed in our previous report (28). These include
the relatively short duration of treatment (median of 77 to
78 days) and the lack of pretreatment echocardiograms.
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Furthermore, this study does not address combination
treatment (phen-fen).
Clinical implications. The results of this study are reas-
suring for the population of patients treated with Dexfen for
three months or less. After discontinuation of treatment for
three to five months, there was no difference in prevalence of
either AR or MR of any severity between treated and
control patients, suggesting that progression is unlikely.
Nevertheless, patients treated with appetite suppressants
who present with a new murmur or clinical symptoms
should undergo the appropriate evaluation as outlined in the
American College of Cardiology/American Heart Associa-
tion Guidelines (43).
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Normal Full excursion of the leaflets to the
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posterior wall by more than 50%.
Moderately impaired Impaired motion by .50%, but
mobility of part of the leaflet
body is maintained.
Severely impaired Complete immobility of the
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Anterior
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mobility that does not impair
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